TAMPA, Fla., June 17, 2024 (GLOBE NEWSWIRE) — Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps as a potential treatment for age-related conditions, today announced that its scientific advisor, Adam Kaplin, M.D., Ph.D., was invited by InSilicoTrials to speak on its panel discussion on June 17, 2024, at the DIA Global Annual Meeting. Along with his fellow panelists, Dr. Kaplin will discuss case studies based on his experience using generative AI to provide data modeling solutions to reduce the time and cost of therapeutic studies while upholding strict patient safety standards.
“The opportunity to participate in the panel, titled, ‘Are Human Patients Needed for Clinical Trials, Tomorrow?’ will allow me to both share my experience using generative AI-powered data modeling in therapeutic trials and to learn from my peers about their experiences,” said Dr. Adam Kaplin, scientific advisor to Telomir. “By partnering with companies like InSilicoTrials, Telomir is able to utilize these technologies to enhance and expedite drug dosing, trial performance, and patient safety while reducing the time and cost of their trials. Using generative AI technologies has the potential to move new therapies into the market much more quickly and safely, improving specific research and development activities by up to 90%.”
DIA 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, biotechnology, medical devices, and related products.
To be added to the Telomir Pharmaceuticals email distribution list, please email telomir@kcsa.com with TELO in the subject line.
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents us with an increased chance of contracting a number of degenerative and age-related diseases. Telomir’s goal is to develop and commercialize Telomir-1 (which is proposed to be dosed orally) for a broad range of age-related inflammatory conditions such as osteoarthritis.
The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.
About InSilicoTrials
InSilicoTrials aims to become the leading problem solver in drug development by leveraging computational modeling and simulation (in silico) techniques. Using AI and advanced predictive technologies, we support emerging biotech and pharma companies by generating robust digital evidence and clinical outcomes. Our in silico methods reduce R&D time and costs, offering virtual patient and AI-enhanced trial accuracy, cloud-based simulations for comprehensive virtual assessments & regulatory-compliant data to support clinical programs.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding completion, timing and anticipated size of the initial public offering and the expected commencement of trading on the Nasdaq.
Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 and the aging process and safety of Telomir-1. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
For further information, please contact:
KCSA Strategic Communications
Phil Carlson
telomir@kcsa.com
Telomir Pharmaceuticals
info@Telomirpharma.com
(813) 864-2558
